Design, Synthesis and Bioactivities of Phenylamino-Pyrimidine Derivatives as Novel Protein Tyrosine Kinase Inhibitors

被引：0

作者：

Hong, Xinfu ^{[1
,2
]}

Kuang, Xianzhao ^{[1
,2
]}

Ding, Guohua ^{[1
,2
]}

Liu, Yilin ^{[1
,2
]}

Liu, Jinlin ^{[1
,2
]}

Zhao, Yanjin ^{[1
]}

Li, Shuxin ^{[1
,2
]}

机构：

[1] Acad Mil Med Sci, Inst Radiat & Irradiat Med, Beijing 100850, Peoples R China

[2] Jiangxi Univ Tradit Chinese Med, Dept Med Chem, Nanchang 330006, Peoples R China

来源：

LETTERS IN DRUG DESIGN & DISCOVERY | 2011年 / 8卷 / 07期

基金：

中国国家自然科学基金;

关键词：

Protein tyrosine kinase; Phenylamino-pyrimidine; Synthesis; Bioactivity; SELECTIVE INHIBITOR;

D O I：

10.2174/157018011796235202

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of novel phenylamino-pyrimidine derivatives were designed and synthesized as antitumor agent based on the lead compound of Imatinib by application of the principle of bioisosterism, hybridization and structural optimization. The bioactivities of the new target compounds were tested against human KU812 cells in vitro, some target compounds show promising activities and can be considered for further development.

引用

页码：596 / 601

页数：6

共 18 条

[1]

ALEXANDER L, 1999, PHARMACOL THERAPEUT, V82, P231

[2] Quantification of the anti-leukemia drug ST1571 (Gleevec™) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry [J].

Bakhtiar, R ;

Khemani, L ;

Hayes, M ;

Bedman, T ;

Tse, F .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 28 (06) :1183-1194

[3]

BHUSHAN N, 2002, CANCER RES, V62, P4236

[4]

CARLO BG, 2003, LANCET ONCOL, V4, P75

[5] RADIOSENSITIZATION EFFECT OF STI-571 ON PANCREATIC CANCER CELLS IN VITRO [J].

Chung, Hye Won ;

Wen, Jing ;

Lim, Jong-Baeck ;

Bang, SeungMin ;

Park, Seung Woo ;

Song, Si Young .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03) :862-869

[6]

DORIANO F, 2002, CURR OPIN PHARMACOL, V2, P374

[7] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].

Druker, BJ ;

Tamura, S ;

Buchdunger, E ;

Ohno, S ;

Segal, GM ;

Fanning, S ;

Zimmermann, J ;

Lydon, NB .

NATURE MEDICINE, 1996, 2 (05) :561-566

[8] Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good? [J].

Drummond, MW ;

Holyoake, TL .

BLOOD REVIEWS, 2001, 15 (02) :85-95

[9]

ELIAS J, 2008, EXPERT OPIN INV DRUG, V17, P1127

[10] Protein kinases as targets for anticancer agents: from inhibitors to useful drugs [J].

Fabbro, D ;

Ruetz, S ;

Buchdunger, E ;

Cowan-Jacob, SW ;

Fendrich, G ;

Liebetanz, J ;

Mestan, J ;

O'Reilly, T ;

Traxler, P ;

Chaudhuri, B ;

Fretz, H ;

Zimmermann, J ;

Meyer, T ;

Caravatti, G ;

Furet, P ;

Manley, PW .

PHARMACOLOGY & THERAPEUTICS, 2002, 93 (2-3) :79-98

← 1 2 →